Cargando…

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions

Detalles Bibliográficos
Autores principales:	Mato, Anthony R., Roeker, Lindsey E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425299/ https://www.ncbi.nlm.nih.gov/pubmed/35021608 http://dx.doi.org/10.3324/haematol.2021.280217

Ejemplares similares

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021)

A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
por: Karr, Matthew, et al.
Publicado: (2023)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2020)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
por: Fürstenau, Moritz, et al.
Publicado: (2021)

Novel agents for chronic lymphocytic leukemia
por: Wu, Mei, et al.
Publicado: (2013)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
por: Cuneo, Antonio, et al.
Publicado: (2019)

Chronic lymphocytic leukemia in China
por: Gale, Robert Peter
Publicado: (2022)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

Therapeutic Targets in Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2020)

T cells in chronic lymphocytic leukemia: can they fight?
por: Vardi, Anna, et al.
Publicado: (2017)

The New Face of Autophagy in Chronic Lymphocytic Leukemia
por: Kopeina, Gelina S., et al.
Publicado: (2023)

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
por: Cheson, Bruce D., et al.
Publicado: (2017)

Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents
por: Tadmor, Tamar, et al.
Publicado: (2021)

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
por: Lansigan, Frederick, et al.
Publicado: (2023)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
por: Sedlarikova, Lenka, et al.
Publicado: (2020)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
por: Seiffert, Martina
Publicado: (2023)

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
por: Lew, Thomas E., et al.
Publicado: (2020)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
por: Mato, Anthony, et al.
Publicado: (2023)

Boosting chemokine receptor recycling: an elixir of life for chronic lymphocytic leukemia
por: Patrussi, Laura, et al.
Publicado: (2018)

A step ahead toward precision medicine for chronic lymphocytic leukemia
por: Patriarca, Andrea, et al.
Publicado: (2020)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression
por: Podaza, Enrique, et al.
Publicado: (2019)

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
por: Mato, Anthony R., et al.
Publicado: (2019)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
por: Smith, Lindsay D., et al.
Publicado: (2019)

RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia
por: Gassner, Franz J., et al.
Publicado: (2020)

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
por: Ricci, Francesca, et al.
Publicado: (2011)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022)

DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag
por: Bagacean, Cristina, et al.
Publicado: (2017)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iaoldrf192sg3do83tm36hihi2